ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
ProKidney Corp. - Class A Ordinary Shares (PROK)
Company Research
Source: GlobeNewswire
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as Senior Vice President of Global Clinical Operations having over 30 years of experience in clinical trial execution WINSTON-SALEM, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced two recent strategic appointments enhancing the leadership team’s expertise in clinical operations and technical operations, positioning the Company for completion of its Phase 3 program and future commercialization. Dr. Ulrich Ernst, PhD joins the Company today as Executive Vice President of Technical Operations, and Mr. Lucio Tozzi was appointed Senior Vice President of Global Clinical Operations on January 22, 2024. Both
Show less
Read more
Impact Snapshot
Event Time:
PROK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PROK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PROK alerts
High impacting ProKidney Corp. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PROK
News
- Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032 [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare movers [Seeking Alpha]Seeking Alpha
- Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations [Yahoo! Finance]Yahoo! Finance
- ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
PROK
Earnings
- 11/14/23 - Beat
PROK
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/23/24 - Form 4
- PROK's page on the SEC website